T1	Participants 79 117	patients with type 2 diabetes mellitus
T2	Participants 231 260	patients with type 2 diabetes
T3	Participants 355 419	patients with type 2 diabetes with suboptimal metabolic control.
T4	Participants 420 488	Patients with a baseline haemoglobin A(1c) (HbA(1c)) of 7.3 to 11.0%
T5	Participants 1712 1900	Addition of the DPP4 inhibitor PHX1149 to a stable regimen of metformin or metformin plus a glitazone in patients with type 2 diabetes was well tolerated and improved blood glucose control
